Document is current

Article History

Accepted: 9 July 2023

First Online: 9 August 2023

Declarations

:

: Not applicable.

: Naeem Bhojani is a consultant for Boston Scientific, Olympus, and Procept BioRobotics; Kevin C. Zorn is a consultant for Boston Scientific, Clarius, Olympus, Zenflow, and Resurge Therapeutics; Bilal Chughtai is a consultant/investigator for Boston Scientific, Prodeon, Olympus, and Resurge; and Dr. Elterman is a consultant/investigator for Boston Scientific, Procept Biorobotics, Olympus, Urotronic, Prodeon, and Zenflow.

: All of the data and material used in this paper are publicly available and have been referenced appropriately.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors have contributed to the development of the concept and design, drafting, and revising of the manuscript: Liam Murad was responsible for acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript; David Bouhadana for drafting of the manuscript and critical revision of the manuscript; David-Dan Nguyen for critical revision of the manuscript; Bilal Chughtai for critical revision of the manuscript; Kevin C. Zorn for critical revision of the manuscript; Naeem Bhojani for critical revision of the manuscript; and Dean S. Elterman for critical revision of the manuscript and supervision. All authors have read and approved the final version of this manuscript.